Biomerica (NASDAQ:BMRA – Get Free Report) and Boston Scientific (NYSE:BSX – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.
Volatility and Risk
Biomerica has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and price targets for Biomerica and Boston Scientific, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biomerica | 1 | 0 | 0 | 0 | 1.00 |
| Boston Scientific | 2 | 8 | 20 | 1 | 2.65 |
Biomerica currently has a consensus target price of $9.00, suggesting a potential upside of 561.76%. Boston Scientific has a consensus target price of $61.43, suggesting a potential upside of 38.59%. Given Biomerica’s higher possible upside, research analysts clearly believe Biomerica is more favorable than Boston Scientific.
Insider & Institutional Ownership
22.3% of Biomerica shares are held by institutional investors. Comparatively, 89.1% of Boston Scientific shares are held by institutional investors. 12.3% of Biomerica shares are held by insiders. Comparatively, 0.3% of Boston Scientific shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Biomerica and Boston Scientific”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biomerica | $4.45 million | 0.94 | -$3.78 million | ($1.64) | -0.83 |
| Boston Scientific | $20.07 billion | 3.20 | $2.90 billion | $2.36 | 18.78 |
Boston Scientific has higher revenue and earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Biomerica and Boston Scientific’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biomerica | -115.50% | -142.81% | -77.83% |
| Boston Scientific | 16.62% | 18.61% | 10.58% |
Summary
Boston Scientific beats Biomerica on 13 of the 15 factors compared between the two stocks.
About Biomerica
Biomerica, Inc. is a medical diagnostics company that develops, manufactures and commercializes products designed to help diagnose and manage gastrointestinal and other health conditions. Its offerings are intended for use by physicians, laboratories and consumers, depending on the product. The company’s principal product is inFoods IBS, a blood-based diagnostic and therapeutic system designed to identify foods that may contribute to symptoms associated with irritable bowel syndrome. The system is intended to support a personalized dietary program under the direction of a healthcare professional.
About Boston Scientific
Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.
